Under the initial EUA , the Lyra ? SARS-CoV-2 Assay real-time RT-PCR test was intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab specimens from patients suspected of COVID-19 by their healthcare provider .
The list of acceptable specimens has been expanded by the CDC to include nasal and nasal turbinate swabs .
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 ( CLIA ) , 42 U .
? 263a , to perform high complexity tests .
EUAs allow for the early availability of important diagnostic tools " when there are no adequate , approved and available alternatives .
" 2  The Lyra ? reagents include unique features that provide for simple transport and storage , improved workflow , shorter time to result , and other benefits that favorably affect diagnostic test outcome .
The Lyra SARS-CoV-2 Assay provides these and certain additional advantages over many other tests currently on the market for this novel coronavirus , including easier set-up and faster time to result .
Quidel Receives CE Mark , Health Canada Authorization  Separately , the Lyra ? SARS-CoV-2 Assay received CE-Mark on @ @ @ @ @ @ @ @ @ @ to market and sell the Lyra ? SARS-CoV-2 Assay in Europe , as well as other countries that accept the CE Mark .
Also , on March 25 , 2020 , Quidel received authorization from Health Canada to market and sell the assay in Canada .
The assay is currently available for sale in the United States under EUA and can be purchased by laboratory professionals through Quidel directly , or through their Cardinal Health representative .
About Quidel Corporation  Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system .
Marketed under the Sofia ? , QuickVue ? , D3 ? Direct Detection , Thyretain ? , Triage ? and InflammaDry ? leading brand names , as well as under the new Solana ? , AmpliVue ? and Lyra ? molecular diagnostic brands , Quidel 's products aid in the detection and diagnosis of many critical diseases and conditions , including , among others , influenza , respiratory syncytial virus , Strep @ @ @ @ @ @ @ @ @ @ occult blood .
Quidel 's recently acquired Triage ? system of tests comprises a comprehensive test menu that provides rapid , cost-effective treatment decisions at the point-of-care ( POC ) , offering a diverse immunoassay menu in a variety of tests to provide diagnostic answers for quantitative BNP , CK-MB , d-dimer , myoglobin , troponin I and qualitative TOX Drug Screen .
Quidel 's research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians ' offices and hospital and reference laboratories .
For more information about Quidel 's comprehensive product portfolio , visit quidel .
Forward-Looking Statements  This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks , assumptions and uncertainties .
Many possible events or factors could affect our future financial results and performance , such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements .
As such , no forward-looking statement can be guaranteed .
Differences in @ @ @ @ @ @ @ @ @ @ a number of factors including , without limitation , fluctuations in our operating results resulting from the timing of the onset , length and severity of cold and flu seasons , seasonality , government and media attention focused on influenza and other respiratory viruses and the related potential impact on humans from such novel influenza or other respiratory viruses , adverse changes in competitive conditions , the reimbursement system currently in place and future changes to that system , changes in economic conditions in our domestic and international markets , lower than anticipated market penetration of our products , the quantity of our product in our distributors ' inventory or distribution channels , changes in the buying patterns of our distributors , and changes in the healthcare market and consolidation of our customer base ; our development and protection of proprietary technology rights ; our development of new technologies , products and markets ; our reliance on sales of our influenza diagnostic tests ; our reliance on a limited number of key distributors ; our exposure to claims and litigation , including the ongoing litigation between the Company and Beckman @ @ @ @ @ @ @ @ @ @ not limited to , infringement litigation ; our need for additional funds to finance our capital or operating needs ; the financial soundness of our customers and suppliers ; acceptance of our products among physicians and other healthcare providers ; competition with other providers of diagnostic products ; adverse actions or delays in new product reviews or related to currently-marketed products by the U .
Food and Drug Administration ( the " FDA " ) or other regulatory authorities or loss of any previously received regulatory approvals or clearances ; changes in government policies ; costs of or our failure to comply with government regulations in addition to FDA regulations ; compliance with government regulations relating to the handling , storage and disposal of hazardous substances ; third-party reimbursement policies ; our failure to comply with laws and regulations relating to billing and payment for healthcare services ; our ability to meet demand for our products ; interruptions in our supply of raw materials ; product defects ; business risks not covered by insurance ; failures in our information technology or storage systems ; our exposure to cyber-based attacks and security @ @ @ @ @ @ @ @ @ @ personnel ; international risks , including but not limited to , compliance with multiple product registration requirements , compliance with U .
and foreign import/export laws , tariffs , exposure to currency exchange fluctuations and foreign currency exchange risk sharing arrangements , longer payment cycles , lower selling prices and greater difficulty in collecting accounts receivable , reduced protection of intellectual property rights , political and economic instability , increased financial accounting and reporting burdens .
taxes , and diversion of lower priced international products into U .
markets ; changes in tax rates and exposure to additional tax liabilities or assessments ; our ability to manage our growth strategy and identify and integrate acquired companies or technologies ; risks relating to the acquisition and integration of the Triage and BNP Businesses ; that we may have to write off goodwill relating to our acquisitions ; the level of our indebtedness and deferred payment obligations ; our ability to generate sufficient cash flow to meet our debt service and deferred payment obligations ; that we may incur additional indebtedness ; that the Senior Credit Facility is secured by substantially all of our @ @ @ @ @ @ @ @ @ @ financial restrictions on the Company ; that an event of default could trigger acceleration of our outstanding indebtedness ; increases in interest rate relating to our variable rate debt ; dilution resulting from future sales of our equity ; volatility in our stock price ; provisions in our charter documents , Delaware law and the indenture governing our Convertible Senior Notes that might delay or impede stockholder actions with respect to business combinations or similar transactions ; and our intention of not paying dividends .
Forward-looking statements typically are identified by the use of terms such as " may , " " will , " " should , " " might , " " expect , " " anticipate , " " estimate , " " plan , " " intend , " " goal , " " project , " " strategy , " " future , " and similar words , although some forward-looking statements are expressed differently .
The risks described in reports and registration statements that we file with the Securities and Exchange Commission ( the " SEC " ) from time to time , should @ @ @ @ @ @ @ @ @ @ undue reliance on these forward-looking statements , which reflect management 's analysis only as of the date of this press release .
Except as required by law , we undertake no obligation to publicly release the results of any revision or update of these forward-looking statements , whether as a result of new information , future events or otherwise .
In This Story  Sign up for our newsletter to get the latest on the transformative forces shaping the global economy , delivered every Thursday .
Email Address*  Location*  Please opt-in to receive news and information about Nasdaq 's services .
If you do not opt-in you will not receive any emails from Nasdaq .
Yes ! I would like to receive Nasdaq communications related to Products , Industry News and Events .
can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy .
